The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

Humacyte has priced the product at $29,500 per unit. This is more expensive than the synthetic vessels already on the market.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the development and commercialization of KETARX™ (Ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, ...

Shares of Travere Therapeutics (NASDAQ:TVTX) surged 14% Tuesday following the company's announcement of a successful Type C ...

The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

(Reuters) - The U.S. government said on Wednesday it will aim for ... first by the new government since the outgoing administration earlier this month released a list of 15 drugs that are set ...

Trump's Administration Aims for 'Greater ... was the first by the new government since the outgoing administration earlier this month released a list of 15 drugs that are set to undergo the ...

Lawmakers unveiled the bill that requires pharmaceutical manufacturers to sell certain drugs to care centers and ... might drop in 2025 Discovery of a new ghostly creature hunting 8,000 metres ...